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Abstract  
 
Mice lacking the adenosine A2A receptor are less sensitive to nociceptive stimuli, and 
A2A receptor antagonists have antinociceptive effects.  We have previously shown a 
marked reduction in the behavioural responses to formalin injection in A2A receptor 
knockout mice. This may be due to the presence of pronociceptive A2A receptors on 
sensory nerves, and if so spinal cords from A2A receptor knockout mice may have 
altered neurochemical responses to a nociceptive stimulus.  We tested this hypothesis 
by studying two parameters known to change with spinal cord activity, NMDA 
glutamate receptor binding and [14C]-2-deoxyglucose uptake, following intraplantar 
formalin injection in wild-type and A2A receptor knockout mice.  In naïve untreated 
A2A knockout mice [14C]-2-deoxyglucose uptake in all regions of the spinal cord was 
significantly lower compared to the wild-type, similar to the reduced NMDA receptor 
binding that we have previously observed.  Following formalin treatment, there was 
an decrease in [3H]MK801 binding to NMDA receptors and an increase in [14C]-2-
deoxyglucose uptake in the spinal cords of wild-type mice, and these changes were 
significantly reduced in the A2A knockout mice.  In addition to altered behavioural 
responses, there are therefore corresponding reductions in spinal cord neurochemical 
changes induced by formalin in mice lacking adenosine A2A receptors. These 
observations support the hypothesis that activation of A2A receptors enhances 
nociceptive input into the spinal cord and suggests a possible role for A2A antagonists 
as analgesics. 
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Introduction 
 
Adenosine can modulate pain pathways, and the nature of this action depends on the 
receptor subtypes involved.  Adenosine acts via four G protein coupled receptors, A1, 
A2A, A2B, and A3.  The A1 and A2A receptor have the highest affinity and are likely to 
be activated at physiological concentrations of adenosine, whereas the A2B and A3 
receptors are more likely to play a role under pathological conditions such as 
ischaemia when high concentrations of adenosine are released [11, 12].  Adenosine 
acts via A1 receptors mainly in the spinal cord to inhibit nociception, whereas A2A 
receptors have a pronociceptive effect which has been suggested to be due to an effect 
on peripheral nerve terminals [32].  In support of these opposing roles of the A1 and 
A2A receptors, A1 knockout mice have enhanced nociceptive responses [19], whereas 
we and others have shown that A2A knockout mice have reduced sensitivity to thermal 
nociceptive stimuli [3, 14, 24].  We have also shown a significant reduction in both 
phases of the nociceptive behaviour of A2A knockout mice subjected to intraplantar 
formalin injection, and a marked antinociceptive effect of the selective A2A antagonist 
5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c)pyrimidine (SCH 58261) in the same test [18].  Another study in mice also reported 
that an A2A–selective antagonist injected locally into the paw caused reduction in both 
edema and pain responses to formalin [4].   
 
In addition to these behavioural changes, we found a large reduction in the level of 
binding of [3H](5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-
5,10-imine ([3H]MK801) to NMDA glutamate receptors in the spinal cord of A2A 
knockout mice, but no change in the binding of [3H]substance P to NK1 receptors, 
showing that removal of the A2A receptor has differential effects on the receptors for 
the two major transmitters released from primary afferent neurones in the spinal cord 
[18].  In A2A receptor knockout mice there are also changes in spinal cord opioid 
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receptor binding that are mirrored by changes in the antinociceptive potency of opioid 
receptor agonists [3].   
 
The presence and function of A2A receptors in the spinal cord are controversial.  
Conflicting results have been obtained from binding studies and autoradiography [3, 
7, 8], and functional studies have reported some inconsistent effects of A2A receptor 
ligands [1, 5, 15, 16, 25, 28, 36].  mRNA for the A2A receptor has been reported to be 
expressed in the dorsal root ganglion but not in the spinal cord [20, 21] suggesting 
that A2A receptors could be present on the peripheral terminals of the sensory nerves 
but not to any significant extent in the spinal cord, as suggested by Sawynok [32].  
More recent studies have however detected mRNA for the A2A receptor in rat and 
mouse spinal cord [6, 16], and it has been suggested that these may on be on 
microglia as A2A knockout mice have reduced responses (allodynia, hypoeralgesia 
and increased spinal cord microglia and astrocytes) in a neuropathic pain model 
thought to involve microglial activation [6].  In summary there seems to be evidence 
for the presence of A2A receptors in the spinal cord but these receptors do not seem to 
exist at a density sufficient to be detected by autoradiography and their functional 
significance is not clear.  The changes that we have observed in spinal cord receptor 
binding in the A2A knockout mice are therefore not likely to be due to the absence of 
A2A receptors in the spinal cord itself [3, 18].  Instead the changes are likely to be 
related to the hypoalgesic phenotype of these mice, and may reflect reduced 
nociceptive input to the spinal cord due to loss of pronociceptive A2A receptors on the 
peripheral terminals of sensory nerves.   
 
To investigate further the hypothesis that the A2A receptor is involved in pain 
pathways, and in particular the activation of sensory nerves which have their synapses 
in the spinal cord, we looked at changes in spinal cord neurochemistry following 
injection of formalin into the hind paw of wild-type and A2A receptor knockout mice.  
Formalin is widely used as an acute nociceptive stimulus, with two distinct phases: 
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the first phase (0-15 min) reflecting mainly direct stimulation of sensory nerves, with 
the second phase (15-60 min) reflecting an inflammatory component [10, 33].  As 
glutamate is the major neurotransmitter released by primary afferent neurones [27], 
we measured binding to ionotropic NMDA glutamate receptors in the spinal cord as 
changes in nerve firing are likely to be followed by changes in receptor binding and 
because changes in the expression and phosphorylation state of NMDA receptor 
subunits in the spinal cord have been reported in the spinal cord after treatment with 
formalin [13, 22].  We have also looked at the in vivo uptake of [14C]deoxyglucose in 
the spinal cords of these mice as a marker of neuronal activity [34], because previous 
studies using this method have shown an increase in the uptake of [14C]2-
deoxyglucose in both phases of the formalin test in both rats and mice [2, 30, 31].   
 
Materials and Methods 
 
Animals.  Wild-type and A2A knockout age-matched male mice on a CD1 background 
[24] aged 8 – 12 weeks were bred from heterozygotes and genotyped at weaning. All 
experiments described followed protocols agreed by the UK Home Office in 
accordance with the Animals (Scientific Procedures) Act 1986, UK.   
 
Formalin treatment.  Mice were lightly restrained before receiving a single 20μl 
injection of 5% formalin solution subcutaneously into the ventral, plantar surface of 
the left hind paw.  Mice were assigned to one of two groups designated ‘early’ or 
‘late’, corresponding to the two phases of the response to formalin.  Mice assigned to 
the ‘early’ group were killed 15 minutes after formalin injection, whereas mice 
designated to the ‘late’ group were killed 60 minutes following formalin injection. 
The spinal cords were dissected out, frozen in isopentane at -25oC and stored at -80°C 
until required.   
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For the study of [14C]-2-deoxyglucose uptake mice designated to the ‘early’ group 
were restrained in a plastic cylinder, their tails warmed under a heat lamp and 
3700kBq/kg [14C]-2-deoxyglucose dissolved in sterile saline (stock concentration of 
3700kBq/ml) was injected intravenously via the tail vein. After five minutes they 
were treated with formalin, then returned to the observation chamber for a further 15 
minutes before being killed. “Late” mice were treated with formalin 15 minutes 
before they were injected with 3700kBq/kg [14C]-2-deoxyglucose. They were then 
returned to the observation chamber for a further 45 minutes before being killed. 
Control mice for each group followed the same treatment protocol as “early” or “late” 
mice but received no formalin injection.  
 
Spinal cord receptor autoradiography.  Sections (20μm) were cut from all four 
anatomical regions of the spinal cord (cervical, thoracic, lumbar and sacral) using a 
crysostat (Microm 505E, Zeiss, UK) maintained at -20°C and thaw-mounted onto 
gelatine-coated slides. Adjacent sections were cut for determination of total binding 
and non-specific binding (NSB). Slides with tissue sections were placed into storage 
boxes containing desiccant (Drierite) for a period of two hours at 40C before being 
frozen at -200C until used.  
 
Binding to NMDA receptors was determined using [3H]-MK801 as previously 
described [18].  Sections were pre-incubated in 50mM Tris buffer (Trizma) at pH 7.4 
containing 1μM glutamate, 1μM glycine and 1μM spermidine for 20 minutes at room 
temperature. Total binding was determined by incubating in the same buffer with 
70nM [3H]-MK801 for 1 hour at 40C, and NSB was determined by the addition of 1 
mM unlabelled MK801.  Sections were washed for a total of 60 seconds in three 
changes of ice-cold, briefly rinsed in distilled water and dried in a stream of cool air.  
 
Slides were placed into autoradiography cassettes and apposed to [3H]-Hyperfilm for 
three weeks alongside [3H]-microscale standards (4048 Bq/mg – 3.74 Bq/mg). The 
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resultant autoradiograms were developed in Develex for 5 minutes, washed in 
distilled water for 30 seconds and fixed in Amfix fixative for 4 minutes, washed for 
30 minutes in distilled water then air-dried.  
 
Autoradiographic assessment of [14C]-2-deoxyglucose uptake.  Sections (20μm) were 
cut, mounted and dried as above, then the slides were apposed for three weeks to 
Kodak MR-1 film alongside [14C]-microscale standards (31.89kBq/g – 1.11kBq/g). 
The resultant autoradiograms were developed in Kodak D-19 for 75 seconds, washed 
in distilled water containing acetic acid for 30 seconds and fixed in Kodak rapid fixer 
for 3 minutes, washed in distilled water for 30 minutes and then air-dried. 
 
Analysis of autoradiographic images.  Quantitative analysis was performed using an 
MCID imaging system (Imaging Research, Canada). For each region of spinal cord 
examined, at least three sections were used for quantification. All anatomical areas of 
the spinal cord were analysed by free-hand drawing and referenced to the rat atlas of 
Paxinos and Watson [29]. For [3H]MK801 binding, measurements were taken from 
laminae I-II, III-VI, VII-IX and X on both left and right sides for each section 
analysed, therefore representing a duplicate determination in each section except for 
lamina X where only one measurement was taken. Although data were originally 
obtained from ipsilateral and contralateral sides of the spinal cord there were no 
significant differences observed between the two sides so data were pooled. There 
were also no differences between the different laminae after either the early or the late 
phase of formalin treatment in the binding of [3H]MK801, so the data were pooled for 
clarity and to provide a more robust comparison between the genotypes.  For [14C]-2-
deoxyglucose uptake the images were not so well resolved but measurements were 
taken from laminae I-VI, VII-IX and X for the naïve mice.  As there were no 
differences between the laminae in these mice and inspection of the films for the 
treated mice did not indicate any obvious visual differences, for the treated mice 
measurements were taken from the whole spinal cord section to improve accuracy and 
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provide a more robust comparison between the genotypes. Radioligand binding was 
quantified by reference to the [3H]-microscale standards and expressed as fmol/mg 
tissue. [14C]-2-deoxyglucose uptake was quantified by reference to the [14C]-
microscale standards and expressed as kBq/g.  
 
Data analysis and statistical procedures.  Because of the different basal values 
observed between naïve wildtype and adenosine A2A receptor knockout mice, data 
were transformed to generate values as a % of control. Control values for [3H]-
MK801 binding were taken from data in [17], while ‘early’ control  values in kBq/g 
for [14C]-2-deoxyglucose uptake averaged 2.50 (wildtype) and 1.46 ( knockout) and 
‘late’ controls averaged 1.24 (wild-type) and 1.15 (knockout), with some regional 
variation.  Statistical analysis was carried out using two-way analysis of variance 
(ANOVA) for factors region and genotype, with post-hoc analysis using Fischer’s 
LSD test where appropriate. Unpaired Student’s t-tests were carried out on the raw 
data to identify differences between control values and data obtained at 15 and 60 
minutes following formalin injection and P<0.05 was defined as significant. 
 
Materials:  [14C]-2-deoxyglucose was from ARC, USA and [3H]-MK801 was from 
Perkin Elmer, USA.  Autoradiography cassettes, [3H]-Hyperfilm and [3H]- and [14C]-
microscales were from G.E. Healthcare, UK.  Develex developer and Amfix fixative 
were from Patterson Scientific, UK.  Drierite dessicant was from VWR, UK, and all 
other drugs and chemicals were from Sigma, UK.   
 
Results 
 
Glutamate receptor binding in mouse spinal cord.  We have previously reported a 
large decrease in [3H]MK801 binding to NMDA receptors in all regions of the spinal 
cords of A2A knockout mice compared to wild-type controls [18].  There were also 
differences in the response of these mice to formalin treatment throughout the spinal 
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cord (Figure 1).  In wild-type mice there was a significant decrease in [3H]MK801 
binding at 15 and 60 minutes in all segments of the spinal cord (P<0.05), whereas 
significant changes were not seen in the A2A receptor knockout mice except at 15 
minutes in the thoracic segment (Figure 1).  Overall there was a significant effect of 
genotype in every region (P<0.05, two-way ANOVA).   
 
Uptake of [14C]-2-deoxyglucose in mouse spinal cord.  The uptake of [14C]-2-
deoxyglucose in all regions of the spinal cords from naïve A2A receptor knockout 
mice was significantly reduced compared to wild-type mice (Figure 2, significant 
effect of genotype, P<0.05, two-way ANOVA).  In wild-type mice treated with 
formalin there was an increase in [14C]-2-deoxyglucose uptake after 60 min which 
achieved statistical significance in the lumbar region only (P<0.05), and this increase 
was not seen in the A2A receptor knockout mice (Figure 3).  Overall there was also a 
significant effect of genotype in the lumbar section (P<0.05, two-way ANOVA).   
 
Discussion 
 
We have previously shown that in A2A receptor knockout mice there is a large 
decrease in NMDA glutamate receptor density as indicated by [3H]MK801 binding 
throughout the spinal cord [18], and we now show that this is accompanied by a large 
decrease in [14C]-2-deoxyglucose uptake in all regions of the spinal cord.  The 
decrease in [14C]-2-deoxyglucose uptake demonstrates reduced spinal neuronal 
activity and, like the change in NMDA receptor binding, may be a result of loss of 
A2A receptors in the spinal cord or, perhaps more likely, reduced sensory nerve 
activity and input into the spinal cord during development due to the loss of 
pronociceptive A2A receptors on peripheral nerves [32].   
 
When wild-type mice were challenged with formalin there was a decrease in NMDA 
receptor binding in all regions of the spinal cord at both 15 and 60 minutes, 
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corresponding to the two phases of the formalin response.  Although the second phase 
of the formalin response primarily involves an inflammatory component rather than 
direct stimulation of sensory nerves by formalin, it is still a nociceptive response as 
indicated by behavioural studies [see eg 18] and therefore involves activation of 
sensory nerves. The NMDA receptor is known to play a role in the second phase of 
the formalin response [9] and the reduction in NMDA receptor binding may be due to 
a rapid desensitisation of the receptors following repetitive stimulation, as has been 
observed in other studies [23, 35].  This decrease in NMDA receptor binding was not 
confined to one side or region of the spinal, so is likely to reflect a generalised 
increase in neuronal traffic up and/or down the spinal cord, possibly corresponding to 
the descending inhibition which is known to result from nociceptive stimulation [26].  
Whatever the mechanism for the decrease, it is clear that this response to formalin is 
greatly reduced in the A2A knockout mice, in parallel with the reduction in 
behavioural responses to formalin [18]. There was also a more localised increase in 
[14C]-2-deoxyglucose uptake after 60 min, particularly in the lumbar region where the 
sensory inputs from the hindpaw enter the spinal cord, which is likely to be a more 
direct consequence of peripheral afferent input.  This response, which reflects changes 
in neuronal excitability in the spinal cord, was also abolished or greatly attenuated in 
the A2A receptor knockout mice confirming a role for these receptors in nociceptive 
stimulation. 
 
In conclusion, our results for two different neurochemical parameters in the spinal 
cord of A2A knockout mice, [3H]MK801 binding and [14C]-2-deoxyglucose uptake, 
show significantly lower basal levels in naïve mice as well as reduced changes after 
formalin treatment.  This supports the suggestion of Sawynok [32] that activation of 
A2A receptors enhances nociceptive input into the spinal cord, and is consistent with 
the antinociceptive effects of A2A antagonists and the reduced nociceptive responses 
seen in A2A knockout mice [3, 6, 14, 18, 24].  Overall these results suggest that A2A 
antagonists may have potential for use as analgesics.   
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Figure Legends 
 
Fig. 1.  Changes in [3H]MK801 binding to NMDA glutamate receptors in spinal cord 
sections from wildtype and adenosine A2A receptor knockout mice following 5% 
formalin injection (mean ± S.E.M., n=4-6). Measurements were taken from (A) 
cervical (B) thoracic (C) lumbar and (D) sacral regions, results for all laminae being 
pooled. Two-way ANOVA revealed a significant effect of genotype in every level of 
the spinal cord following formalin injection (P<0.05). Unpaired t-tests were carried 
out on non-transformed data to reveal any differences between control values and the 
data obtained at 15 and 60 minutes after formalin injection * = P<0.05 time point vs 
control. Filled circles represent wild-type and open circles represent adenosine A2A 
receptor knockout mice. 
 
Fig. 2.  Uptake of [14C]-2-deoxyglucose into spinal cord sections from wildtype and 
adenosine A2A receptor knockout mice (mean ± S.E.M., n=7-11). Measurements were 
taken from (A) cervical (B) thoracic (C) lumbar and (D) sacral regions. Two-way 
ANOVA revealed a significant difference between genotypes (P<0.05) in all regions. 
In all cases filled bars represent wild-type and open bars represent adenosine A2A 
receptor knockout mice. 
 
Fig. 3.  Uptake of [14C]-2-deoxyglucose into spinal cords from wildtype and 
adenosine A2A receptor knockout mice following 5% formalin injection. (mean ± 
S.E.M., n=4-6) Measurements were taken from (A) cervical (B) thoracic (C) lumbar 
and (D) sacral regions. Two-way ANOVA revealed a significant effect of genotype in 
lumbar sections of the spinal cord (P<0.05). Unpaired t-tests were carried out non-
transformed raw data to reveal any differences between control values and the data 
obtained at 15 and 60 minutes after formalin injection * = P<0.05 time point vs 
control. Filled circles represent wild-type and open circles represent adenosine A2A 
receptor knockout mice. 
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